Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
150,4 EUR | +1,11% | +2,45% | +23,18% |
09:42 | AstraZeneca's Tagrisso plus chemo krijgt goedkeuring in China | AN |
09:04 | China keurt Tagrisso-chemo combo van AstraZeneca goed als eerstelijnsbehandeling | RE |
Omzet 2024 * | 51,66 mld. 48,29 mld. | Omzet 2025 * | 55,54 mld. 51,92 mld. | Marktkapitalisatie | 247 mld. 230 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 8,76 mld. 8,19 mld. | Nettowinst (verlies) 2025 * | 10,42 mld. 9,74 mld. | EV/omzet 2024 * | 5,18 x |
Nettoschuld 2024 * | 20,76 mld. 19,41 mld. | Nettoschuld 2025 * | 14,18 mld. 13,25 mld. | EV/omzet 2025 * | 4,69 x |
K/w-verhouding 2024 * |
28,1
x | K/w-verhouding 2025 * |
23,6
x | Werknemers | 89.900 |
Dividendrendement 2024 * |
1,94% | Dividendrendement 2025 * |
2,04% | Vrij verhandelbaar | 96,64% |
Recentste transcriptie over AstraZeneca PLC
1 dag | +1,09% | ||
1 week | +2,45% | ||
Lopende maand | +4,92% | ||
1 maand | +4,55% | ||
3 maanden | +22,98% | ||
6 maanden | +23,94% | ||
Lopend jaar | +23,18% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01-10-12 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01-08-21 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01-10-17 |
Philip Broadley
BRD | Director/Board Member | 63 | 27-04-17 |
Director/Board Member | 68 | 01-04-99 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-06-24 | 150,5 | +1,21% | 2 010 |
25-06-24 | 148,7 | +0,47% | 5 323 |
24-06-24 | 148 | +0,20% | 3 617 |
21-06-24 | 147,7 | +0,54% | 7 285 |
20-06-24 | 146,9 | +0,41% | 3 724 |
uitgestelde koers Xetra, 26 juni 2024 om 11:25 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,19% | 815 mld. | |
+45,51% | 654 mld. | |
-6,09% | 354 mld. | |
+21,92% | 337 mld. | |
+3,60% | 229 mld. | |
+14,08% | 219 mld. | |
+10,86% | 171 mld. | |
-2,78% | 159 mld. | |
+1,73% | 122 mld. |